Tetra Bio-Pharma Offers Update on Drug Development Program

- February 12th, 2019

Tetra Bio-Pharma announced it decided to moved up the development of its second-generation drug inhalation program.

Tetra Bio-Pharma (TSXV:TBP,OTCQB:TBPMF) announced it decided to moved up the development of its second-generation drug inhalation program.

As quoted in the press release:

During the last quarter of 2018, the Corporation began preparations for a research site in the United States to conduct its fibromyalgia clinical trial and we are intent on expanding clinical sites in Canada and in the USA in 2019.

“We previously communicated that after reviewing the human clinical data, Tetra anticipated proceeding into phase 2 clinical trials in fibromyalgia patients,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “We are committed to this target and plan to accelerate this development in the USA as well. Tetra has and continues to gain tremendous credibility within the medical community. We earned this credibility because of our clinical studies and exhaustive characterization of the pharmaceutical composition of cannabis-derived smoke and vaporization products. Overall, 2018 was a productive year after completing several clinical trials and we expect 2019 to build on this as we accelerate this program.”

Click here to read the full press release.

Get the latest Cannabis Investing stock information

Get the latest information about companies associated with Cannabis Investing Delivered directly to your inbox.

Cannabis Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *